Quest for Tangible Biomarkers for Triple-Negative Breast Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30987974.
- Also identified by DOI 10.1158/0008-5472.CAN-19-0416.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Identification of key molecular networks involved in triple-negative breast cancer (TNBC) growth and metastasis will increase our mechanistic understanding of this disease and pave the way for the development of novel therapeutic interventions. The study by Khawaled and colleagues points to a direct antimetastatic function of WW domain-containing oxidoreductase (WWOX) in TNBC and identifies the Myc/miR-146a/fibronectin axis as a molecular mediator of the tumor-suppressive function of WWOX. This information can potentially be used to identify actionable nodes for targeting TNBC, a breast cancer subtype otherwise characterized by the absence of markers.<i>See related article by Khawaled et al., p. 1784</i>.
Medical subject headings
- Triple Negative Breast Neoplasms